ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Call for Patient Participation in The University of Michigan Judith Tam ALK Lung Cancer Research Initiative
The University of Michigan Judith Tam ALK Lung Cancer Research Initiative is recruiting ALK positive NSCLC patients for extensive and sustained studies of the course of each individual’s disease. Their research is enabled by the continuing donation of patients’ blood samples, tumor tissue samples, and/or malignant fluid as each may be available over time for…
-
Announcing the ALK International Development Alliance (IDA)
As part of the ALK Positive mission statement the ALK Positive Inc Board of Directors is committed to assisting ALK patients worldwide. Whilst there are many international members in the independent ALK Facebook Support Group, we are also greatly encouraged by the numerous international patients and caregivers who have subscribed to our newsletter. Amongst other…
-
The ALK Positive Lung Cancer Registry and Survey Need You!!
What do patients that go only a short time before tumor progression have in common? What do patients that have many years before tumor progression have in common? What do patients experiencing a lot of problems with adverse effects with ALK TKIs have in common? Is exercise associated with cancer outcomes, or quality of life?…
-
You Can Find a Clinical Trial with the Help of ALK Positive Inc.
At any juncture in treatment, those with ALK Positive cancers are faced with hard choices. Whether you are first starting treatment or you are changing treatment due to progression or side effects, multiple options may be available. At these critical decision points, a clinical trial could be an excellent choice. You may trust your doctor…
-
PATIENT SPOTLIGHT: Andrej Krivda, Wettingen, Switzerland
We interviewed fellow ALKie Andrej Krivda on his very interesting journey with ALK+ lung cancer and all the unexpected twists and turns he’s had to navigate since diagnosis. Andrej is the very first person to enter the Nuvalent NVL-655 clinical trial in Spain and one of the first patients to take part in the trial…
-
Healthy Recipe: Salmon Piccata over Pasta
Our “Practical Chef” and fellow ALKie, Juli Posner shares one of her favorite healthy recipes. “I love Salmon, and I love lemon. This quick fancy ,but easy, recipe incorporates both. Crispy pan Sautéed Salmon tossed in a quick lemon butter sauce will give you a restaurant worthy dinner that is on the table in less…
-
Introducing ALK Positive Italia An interview with Founder, Patty Saccenti
ALK Positive, Inc has introduced a section in our newsletter to feature international (non-US) ALK patient groups/organizations. If you would like your group/organization to be featured in a future newsletter, please contact Duncan Preece at duncan.preece@alkpositive.org In this issue, we are introducing ALK Positive Italia and have interviewed the founder, Patty Saccenti.
-
Pearl Couscous and Lentil Salad Recipe By chef, fellow ALKie, Juli Posner
This salad is so colorful and fresh, it looks gorgeous on any buffet table. It can be a side, yet it doubles as the main event if you add your favorite protein! (Shrimp works beautifully). With lots of texture from crunchy cucumbers, salty brininess from Kalamata olives, and sweetness from golden raisins, it’s a virtual…
-
The New ALK Inhibitor: NVL-655 Trial Expands to Europe!
Who is this trial for: NVL-655 is a 4th generation, brain-penetrant, ALK TKI inhibitor created to overcome several limitations observed with currently available therapies. NVL-655 is designed to have activity in tumors that have developed resistance to first, second, and third-generation ALK inhibitors, including tumors with the solvent front G1202R mutation or compound mutations G1202R/L1196M…
-
ALK Positive and LUNGevity Foundation Announce Recipients of the 2022 ALK-Positive Research Awards
To transform advanced ALK-positive lung cancer into a chronic or curable disease, ALK Positive to award $1.75 million through their research award program WASHINGTON, DC (December 1, 2022)— Patient organization ALK Positive, in partnership with LUNGevity Foundation, announced the 2022 recipients of the ALK Positive/LUNGevity ALK-Positive Lung Cancer Research Awards. The grant monies, totaling $1.75…
-
Groups Award Two Grants for ALK-positive Lung Cancer Research
(December 28, 2022) – ALK Positive Inc. (ALK Positive) and The Lung Cancer Research Foundation (LCRF) announce funding of two ALK-positive related lung cancer projects. These grants, totaling $500,000, are awarded to researchers whose projects are focused upon transforming care and improving outcomes for patients with ALK-positive non-small cell lung cancer (NSCLC). “This is an…
-
Moderna’s Cancer Vaccine Program
Highly successful Covid vaccines have raised the question of ‘why not cancer vaccines?’, a question of great interest and financial contribution for the ALK Positive NSCLC community in recent years. Somewhat under the radar of our members is Moderna, Inc.’s multi-cancer clinical trial for their personalized mRNA vaccine that started in 2017. The trial is…